Date of the event

Thursday September 8, 2016 from 5:30 PM to 8:45 PM EDT
Add to Calendar 

Location of the event

255 Main St.
Cambridge, MA 02142

Driving Directions 

About Us

Health Innovators (501(c)3 non profit organization with 13,000 member) mission is to become the premier place for digital health tech entrepreneurs to innovate and build businesses that will solve our healthcare issues, improve patient outcomes, and reduce costs in a meaningful and impactful way.

What we offer?

  • Digital health accelerator program
  • Custom software development
  • Equity crowdfunding
  • Job board

Check out last event photos

Some of our last events photos

What is Health Innovators?

Contact Health Innovators


Phone: 617.871.9286


Volunteer at Health Innovators

HI has 20 team members with 5 Doctors, 4 MBA's and 10 Masters. We are a highly educated team with a mission to provide you all the resources needed to be successful in healthcare Innovation. Join our team to improve your visibility and become hyper networked. We are looking for help in Grant writing, Marketing and new business development.







How Will Precision Medicine Revolutionize Healthcare

Please note that this event will open for networking at 5:30 pm.

Join us for healthy refreshments, including sandwiches and nonalcoholic drinks.

Price: $30 until September 7th at 8:00 pm; $40 after then and at the door as ticket availability permits.


Microsoft Corporate Center
255 Main St.
Cambridge, MA 02142
(Please note: do not go to the Microsoft NERD Center on 1 Memorial Dr. which is often confused with this location as it is right around the corner.) 

Networking - 5:30 pm to 6:40 pm 
Program: 6:40 pm to 8:00 pm 
Networking: 8:00 pm to 8:45 pm

Far too many diseases do not have a proven means of prevention or effective treatments. We must gain better insights into the biological, environmental, and behavioral influences on these diseases to make a difference for the millions of Americans who suffer from them. Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. While some advances in precision medicine have been made, the practice is not currently in use for most diseases.

That’s why on January 20, 2015, President Obama announced the Precision Medicine InitiativeŽ (PMI) in his State of the Union address. Through advances in research, technology and policies that empower patients, the PMI will enable a new era of medicine in which researchers, providers and patients work together to develop individualized care.

The President called for $215 million in fiscal year 2016 to support the Initiative, which includes several components with efforts from across the federal government. Of this total proposed budget, $130 million was allocated to NIH to build a national, large-scale research participant group, called a cohort, and $70 million was allocated to the National Cancer Institute to lead efforts in cancer genomics as part of PMI for Oncology.



Raju Kucherlapati, Ph.D. (panelist)


Raju Kucherlapati, Ph.D., is the Paul C. Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham and Women’s Hospital.

Dr. Kucherlapati was the first Scientific Director of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. His research focuses on gene mapping, gene modification, and cloning disease genes. From 1989-2001, Dr. Kucherlapati was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department at the Yeshiva University Albert Einstein College of Medicine. He was previously a professor in the Department of Genetics at the University of Illinois, College of Medicine. He began his research as an assistant professor in the Department of Biochemical Sciences at Princeton University.

He has chaired numerous NIH committees and served on the National Advisory Council for Human Genome Research and the NCI Mouse Models for Human Cancer Consortium. He is also a member of the Cancer Genome Atlas project of the National Institutes of Health. He is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science.

Dr. Kucherlapati received his B.S. and M.A. in Biology from universities in India, and he received his Ph.D. from the University of Illinois at Urbana, as well as conducting post-doctoral work at Yale University.

Jeffrey A. Golden, M.D. (panelist)

Jeffrey A. Golden is the Ramzi S. Cotran Professor of Pathology at Harvard Medical School and the Chair of Pathology at the Brigham and Women’s Hospital.  He received his BA from the University of California, San Diego and his MD from the University of Pennsylvania.  He trained in anatomic pathology and neuropathology at the Massachusetts General Hospital followed by postdoctoral training in the Department of Genetics at Harvard Medical School at which time he was an Instructor in the Department of Pathology at Brigham and Women’s Hospital.  He returned to the University of Pennsylvania School of Medicine and the Children’s Hospital of Philadelphia as an Assistant Professor of Pathology and Laboratory Medicine in 1996 rising to the rank of Professor in 2008.  In 2003 he established the division of Developmental Biology for Pediatric Disorders at the Children’s Hospital of Philadelphia and in 2008 was appointed Pathologist-in-Chief at the Children’s Hospital of Philadelphia.  In 2012 he moved back to Boston to assume the Chair of the Department of Pathology at the Brigham and Women’s Hospital.  There he is leading the development and implementation of Computational Pathology and Precision Medicine.  In addition to his local roles he is a past president of the American Association of Neuropathologists, an Associate Editor for the Journal of Neuropathology and Experimental Neurology, and a member of many editorial boards.  He has served on many international, national and local committees, has organized numerous national and international meetings, and is a regular grant reviewer for international funding agencies and the NIH, including chairing numerous study sections.  Finally, his work has been recognized with a number of awards including the Litchfield Lectureship at Oxford College, the Dorothy Russell Memorial Lectureship from the British Neuropathology Society, and twice the Weil Award from the American Association of Neuropathologists.

Candida Fratazzi, MD (panelist)

Dr. Fratazzi has 25 years’ experience in biomedical research. Dr Fratazzi devised the concept of a Strategic Clinical Innovation Organization (SCIO) and founded the first SCIO –Boston Biotech Clinical Research (BBCR), LLC in 2009, with the objective of actively contributing to innovation in clinical research. Dr. Candida Fratazzi is an Orphan Diseases expert: she has worked in cystic fibrosis, Fabry disease, Gaucher’s disease, and multiple sclerosis projects. As the President of BBCR, LLC, Dr. Fratazzi acts as a consultant to biotech, pharmaceutical and medical device companies of all sizes, advising her clients on optimum clinical plan development and how to design clinical trials that reduce the risk of late-stage failure. Dr Fratazzi has held senior positions at Wyeth, Shire, TKT, Vitex and Altus Pharmaceuticals. Her experience encompasses all stages of clinical research. Her most recent achievements include: Recipient of the Cambridge Award for Pharmaceutical Consultant 2013, Developed and presented workshops: BIO Conference 2011 and 2012, Invited speaker: ACRP 2012; MBC 2010 and 2011; GLG 2011 and authored several book chapters.

Jack Whelan (panelist)

Jack is a 7 yr survivor of a rare, incurable blood cancer moving from a career IT Research Analyst to Research Advocate.  Travel with Jack on an intensely personal and oft-humorous bumpy ride on the road to Personalized Medicine still under construction while he is treated for a rare, incurable blood cancer. Encounter some relapsed/refractory detours, conflicting signals and biomarkers, inhibiting regulatory roadblocks and potholes in the healthcare system.  Learn why Jack, not much of beer drinker himself hangs a bottle of Guinness on his chemo infusion rack and speaker’s podium. Using business communications and research skills from his career as a Wall Street Research Analyst in Information Technology (IT) and career Sales VP in IT, he now helps bridge the communications gap between life sciences, medical professionals and patients as a Patient Advocate, Research Advocate and Legislative Advocate.

Jack hopes all of us appreciate the value and noble work of life sciences employees and companies involved in cancer research and care.  A decided friend to BioPharma as an engaged, informed e-Patient Opinion Leader (POL) and advocate he regularly speaks to and for these companies, to open much-needed, lines of communications with patients, providers and policymakers.

He encourages all patients to explore novel targeting agents many of which are now in Clinical Trials.  Using genetic and genomic information to develop new disease-specific targeted therapeutics might be safer and more effective treatment than conventional chemotherapy.  Jack’s a frequent speaker and participant at the best industry and advocacy conferences in the Americas and Europe sharing his engaging, gripping, hopeful and fun story about survival.
Jack understands the realities of his blood cancer as he has repeatedly relapsed and has been refractory to most of the therapies received thus far; however his goal is repeated periods of progression free survival during which the promise of science and delivery of successful therapeutics will be achieved.